Henney, A. E., Riley, D. R., O'Connor, B., Hydes, T. J., Anson, M., Zhao, S. S., . . . Cuthbertson, D. J. (2024). Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all‐cause mortality in adults, compared with bisphosphonates: An analysis of real‐world, cohort data, with a systematic review and meta‐analysis. Wiley. https://doi.org/10.1111/dom.15708
Citazione stile Chigago Style (17a edizione)Henney, Alex E., David R. Riley, Ben O'Connor, Theresa J. Hydes, Matthew Anson, Sizheng Steven Zhao, Uazman Alam, e Daniel J. Cuthbertson. Denosumab, for Osteoporosis, Reduces the Incidence of Type 2 Diabetes, Risk of Foot Ulceration and All‐cause Mortality in Adults, Compared with Bisphosphonates: An Analysis of Real‐world, Cohort Data, with a Systematic Review and Meta‐analysis. Wiley, 2024. https://doi.org/10.1111/dom.15708.
Citatione MLA (9a ed.)Henney, Alex E., et al. Denosumab, for Osteoporosis, Reduces the Incidence of Type 2 Diabetes, Risk of Foot Ulceration and All‐cause Mortality in Adults, Compared with Bisphosphonates: An Analysis of Real‐world, Cohort Data, with a Systematic Review and Meta‐analysis. Wiley, 2024. https://doi.org/10.1111/dom.15708.